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Brief Definit ive Report
Parkinson’s disease (PD) is a common progres-
sive neurodegenerative disorder of the central 
nervous system (CNS), which has as part of 
its core pathology the loss of the nigrostriatal 
dopaminergic neurons. The causes and mecha-
nisms of such selective neuronal loss are not 
well defined, but recent studies have high-
lighted an important role for mitochondrial 
dysfunction, especially Complex I (Schapira 
et al., 1990; Schapira, 2006; Dawson et al., 2010). 
In fact, some of the most widely used experi-
mental models of PD, such as 6-hydroxydopa-
mine (6-OHDA) and rotenone, mediate at 
least part of their toxicity through this pathway 
(Dabbeni-Sala et al., 2001; Sherer et al., 2003). 
On this basis, the possibility that protection of 
mitochondrial function could limit neuronal 
loss and act therapeutically has been suggested 
as a possible treatment for PD. We have previ-
ously identified a novel RNA expressed during 
human CMV (HCMV) infection that func-
tions to prevent cell death (Reeves et al., 2007). 
This viral noncoding RNA, termed the 2.7 
transcript, is essential to maintain high levels of 
energy production in infected cells (Reeves 
et al., 2007). The mechanism by which 2.7 
protects infected cells is novel and appears to 
be mediated by a direct interaction between 
2.7 and Complex I (Reeves et al., 2007). We 
therefore sought to investigate, using both 
in vitro and in vivo models to imitate dopa-
minergic cell loss in PD, whether a truncated 
form of 2.7 (p137) containing the putative 
TRL4 subdomain (Bergamini et al., 1998) still 
prevents dopaminergic neuronal death.
Over the past decade, much research has 
been done on the delivery of therapeutic gene 
products to restore the impaired dopaminergic 
system in experimental models of PD. Many of 
these attempts have been based on viral vectors 
involving either knockin (overexpression) gene 
therapy (Luo et al., 2002) or knockout (inter-
ference) gene silencing (Outeiro et al., 2007). 
However, several problems are associated with 
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Parkinson’s disease (PD) is a neurodegenerative disorder that results in the loss of nigro­
striatal dopamine neurons. The etiology of this cell loss is unknown, but it involves abnor­
malities in mitochondrial function. In this study, we have demonstrated that the 
administration of a novel noncoding p37 RNA, derived from the human cytomegaloviral 
2.7 transcript, can prevent and rescue dopaminergic cell death in vitro and in animal 
models of PD by protecting mitochondrial Complex I activity. Furthermore, as this p37 
RNA is fused to a rabies virus glycoprotein peptide that facilitates delivery of RNA across 
the blood–brain barrier, such protection can be achieved through a peripheral intravenous 
administration of this agent after the initiation of a dopaminergic lesion. This approach has 
major implications for the potential treatment of PD, especially given that this novel agent 
could have the same protective effect on all diseased neurons affected as part of this 
disease process, not just the dopaminergic nigrostriatal pathway.
© 2012 Kuan et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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RESULTS AND DISCUSSION
The RVG9R–p37 system protects dopaminergic cells  
in both in vitro and in vivo models of PD
Our initial experiments clearly showed that the p137 RNA 
complexed with RVG9R peptide could protect SH-SY5Y 
cells from exposure to rotenone, a highly selective inhibitor to 
mitochondrial Complex I (Fig. 1 c; Betarbet et al., 2000). 
Conjugation with the RVG9R peptide enabled the delivery of 
p137 RNA into neurons of both dopaminergic and nondopa-
minergic systems (Fig. 1, d and e) and protected primary fetal 
dopaminergic cells from a 6-OHDA insult (Fig. 1 f). Such 
protection was not observed using a range of RNA and pep-
tide controls of various sizes, which included RVG9R–
antisense p137, RVMat9R–p137 (comprising a control peptide 
unable to bind to AChR), or control RVG9R–pXef , which 
encodes the Xenopus laevis elongation factor 1a (Fig. 1). 
such delivery systems, such as the invasive nature of the intra-
cerebral procedure to administer therapeutic agents and the 
nonspecific expression of these agents outside neural cells. 
Recently, Kumar et al. (2007) described a method to deliver 
short interfering RNA (siRNA) to the brain using a small 
peptide derived from the rabies virus glycoprotein (RVG). 
This peptide binds to the acetylcholine receptor (AChR) 
exclusively expressed in CNS cells (Hanham et al., 1993). 
Although the RVG peptide itself has no RNA binding affin-
ity, a derivative containing nonamer arginine residues 
(RVG9R) binds RNA efficiently and delivers the RNA 
cargo across the blood–brain barrier after peripheral adminis-
tration (Kumar et al., 2007). We therefore also sought to test 
whether the transvascular administration of the p137 RNA 
could be successfully delivered in this way to prevent dopa-
minergic cell loss in models of PD.
Figure . Delivery of RVG9R–p37 to cultured cells in vitro prevents neurotoxin­induced cell death. (a) Representative photomicrographs on 
the expression of a3/a5 nicotinic AChR (green) on HEK293, U373, and SH-SY5Y cells. Nuclei were counterstained with Hoechst (blue). (b) Representative 
photomicrographs showing the delivery of unlabeled p137 RNA in U373 cells treated with p137 alone, control RVMat9R peptide–conjugated p137, 
RVG9R–p137, or RVG9R–pXef, as detected using FISH to detect p137 RNA (red). (c) Treatment of RVG9R–p137 but not RVG9R complexed with the control 
antisense p137 RNA (a.s. p137), or the control RVMat9R peptide complexed with the p137 RNA significantly protected SH-SY5Y cells from rotenone 
(Rot)-mediated cell death analyzed by TUNEL staining. (d and e) FITC-tagged p137 RNA could be detected in both cholinergic (d) and dopaminergic (e) 
neurons after incubation with rat E13.5 primary cortical (CTx) and VM cells, respectively. FITC signals (yellow) were colocalized with Hoechst (blue), AChR 
(green), and ChAT/TH (red). (f) Numbers ofTH+ cells in untreated VM cultures (con) or in VM cultures insulted with 6-OHDA, in the presence of increasing 
concentrations of RVG9R–p137 or RVG9R–pXef, were quantified. The proportion of TH+ cells was calculated against the total number of Hoechst+ cells. 
(a–f) Data were obtained from three (a–c), two (d and e), and six (f) independent experiments. Data represent mean ± SEM; **, P < 0.005; ***, P < 0.001, 
compared with the neurotoxin only group. Bars: (a and b) 30 µm; (d) 25 µm; (e) 40 µm.
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interacting with Complex I in the nigral tissue of rats re-
ceiving this treatment. We used reversible cross-linking of 
RNA–protein conjugates combined with Complex I immuno-
precipitation. Native Complex I from the nigra of rats 
pretreated with RVG9R–p137 clearly resulted in the co-
precipitation with p137 (Fig. 2 a). This interaction was 
specific for native (assembled in the mitochondria) Complex I, 
as immunoprecipitation of mitochondrial Complex IV showed 
no such interaction with p137 RNA. This was recapitulated 
when using primers to amplify the full-length p137 product 
from RNA immunoprecipitations (Fig. 2 b), arguing that 
full-length p137 was associated with Complex I. We ob-
served that the specific interaction between p137 and Com-
plex I was more pronounced in RVG9R–p137-pretreated 
rats subsequently exposed to 6-OHDA compared with the 
unlesioned animals (Fig. 2 a). There was no interaction be-
tween pXef and Complex I using pXef-specific PCRs of the 
same cDNAs used (Fig. 2 a).
To confirm this interaction between p137 and mitochon-
dria, we also analyzed the distribution of p137 between the 
mitochondrial and cytosolic fractions of the isolated nigra from 
rats receiving RVG9R–p137 (Fig. 2 c). This showed the 
presence of p137 RNA by RT-PCR specifically in RVG9R–
p137-treated rats, as expected (Fig. 2 c, left). We then frac-
tionated mitochondria from the nigra of these rats, confirmed 
purity (Fig. 2 c, right) by Western blot detection of GAPDH 
(cytosol specific) and HSP60 (mitochondria specific), and ana-
lyzed levels of p137 RNA (Fig. 2 c, middle).Taking into 
account contamination of the cytosol with mitochondrial 
markers but little contamination of the mitochondrial fraction 
with cytosol, this analysis showed that at least half of the p137 
delivered was associated with mitochondria. This is consistent 
with mitochondria being a major but not exclusive site of 
action of p137 as the cytosolic fraction also contains noticeable 
levels of p137. This is not unexpected given that the viral 2.7 
RNA is likely to be multifunctional and is known to interact 
Similarly, p137 RNA complexed with RVG9R peptide could 
also be delivered to the a3/a5 nicotinic AChR+ U373 cell 
line (Fig. 1, a and b). In contrast, incubation of p137 RNA 
alone, with the RVMat9R–p137 complex, or with the 
RVG9R–pXef complex failed to result in p137 delivery to 
U373 cells (Fig. 1 b).
Based on the in vitro results, we tested the ability of 
RVG9R–p137 to protect dopaminergic cell loss against 
6-OHDA neurotoxicity in vivo. Adult male rats were stereo-
tactically injected with peptide–RNA complex containing 
2.5 µg RNA into the dopaminergic cell bodies at the level of 
the substantia nigra pars compacta (SNc) 3 d before an acute, 
intranigral 6-OHDA insult. We observed the expected func-
tional (Table 1) and phenotypical (not depicted) deficits in 
those rats that were given RVG9R–pXef pretreatment, 
whereas rats pretreated with equivalent doses of RVG9R–
p137 showed significant attenuation of the lesioning effects.
As the RVG peptide was originally engineered to enable its 
RNA cargo to cross the blood–brain barrier and target its de-
livery to the brain, we examined the possibility of using a trans-
vascular approach for RVG9R–p137 administration. Rats were 
treated with an intravenous injection of 300 µg of RVG9R–
p137, via the tail vein, 3 d before an intranigral 6-OHDA lesion. 
Consistent with our observations using intranigral delivery, rats 
pretreated transvascularly with RVG9R–p137 performed sig-
nificantly better than those receiving RVG9R–pXef on a bat-
tery of behavioral tests (Table 1). This correlated well with 
immunohistochemical analysis, showing that the RVG9R–p137 
pretreatment significantly protected the nigrostriatal dopami-
nergic system from the lesion (not depicted).
RVG9R–p37 mediates neuroprotection by protecting 
mitochondrial Complex I activity
To verify that the RVG9R–p137-mediated neuroprotection 
was associated with an interaction between p137 and mito-
chondrial Complex I, we analyzed whether p137 was physically 
Table . Summary of scores in the drug-induced rotation tests, forelimb cylinder test, and forelimb stepping tests  
in the RVG9R–p137 and RVG9R–pXef receiving groups
Groups Treatment  
(no. of rats)
Amphetamine-induced 
rotation
Apomorphine-induced 
rotation
Contralateral  
forelimb use
Contralateral forelimb 
stepping (no. of 
adjustment steps)
turns/min turns/min %
Pre-lesion treatment 
(intranigral)
pXef (10) 
p137 (10)
6.45 ± 1.04
0.32 ± 0.69c
4.63 ± 1.16
1.57 ± 1.08b
10.37 ± 3.57
40.24 ± 7.95c
2.00 ± 0.31
11.22 ± 0.81c
Pre-lesion treatment 
(intravenous)
pXef (10) 
p137 (12)
10.93 ± 6.80
1.61 ± 4.53a
4.34 ± 0.71
0.35 ± 1.32c
1.47 ± 2.31
41.61 ± 19.96b
2.33 ± 1.03
10.33 ± 2.81c
Post-lesion treatment 
(intranigral)
pXef (9) 
p137 (10)
4.72 ± 1.65
0.44 ± 1.82b
0.85 ± 0.72
0.53 ± 0.40
16.98 ± 16.74
40.56 ± 12.74a
6.22 ± 1.20
7.91 ± 1.38
Post-lesion treatment 
(intravenous)
pXef (6) 
p137 (6)
5.75 ± 3.41
0.82 ± 0.77b
0.70 ± 0.31
0.12 ± 0.28a
19.07 ± 11.89
57.03 ± 8.19c
4.17 ± 1.94
7.50 ± 1.05a
p137 encodes the neuroprotective domain of the human cytomegaloviral 2.7 transcript. Data shown for all treatment groups are derived from one observation, involving all 
lesioned animals, from four independent experiments over a time span of 2 yr, using multiple batches of RVG9R peptide and RNAs. Data represent mean ± SEM.
aP < 0.05.
bP < 0.01.
cP < 0.001.
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We then examined whether RVG9R–p137 delivery 
offered protection at the level of enzyme activity of Complex I 
in the SNc in the presence of the 6-OHDA insult (Fig. 2 d). 
with other cellular targets (Reeves et al., 2007); what is impor-
tant is that its major action here is through a selective inter-
action with mitochondrial Complex I.
Figure 2. p37 interacts with mitochondrial Complex I in the substantia nigra and protects Complex I activity from a 6­OHDA–induced deficit. 
(a) Single cell suspensions of the nigra from rats intranigrally pretreated with RVG9R–p137 (p137) or control RVG9R–pXef (pXef), and subsequently left un-
lesioned (6-OHDA) or lesioned (+6-OHDA), were analyzed for p137–Complex I interaction by RNA immunoprecipitation. Immunoprecipitates using control Ig 
antibody, anti–Complex IV antibody (C4), or anti–Complex I antibody (C1) were analyzed by p137 RT-PCR for the presence of coimmunoprecipitated p137 
RNA. Starting samples (5% of samples used for immunoprecipitation) were also directly amplified by RT-PCR to determine input levels of p137 (in).  
RNA immunoprecipitations were performed twice independently, from two different in vivo experiments, and the data shown are from one of these experiments, 
which has been analyzed three times and showed the same patterns of PCR bands. (b) Single cell suspensions of the nigra of rats intranigrally pretreated with 
RVG9R–p137 were analyzed for the interaction of full-length p137 with Complex I by RNA immunoprecipitation. Immunoprecipitates of cells using anti–
Complex I or anti–Complex IV antibody were analyzed by a p137-specific RT-PCR for the presence of coimmunoprecipitated p137 RNA. For positive controls, 
full-length p137 RNA with (+) or without () RT was amplified as well as RNA from HCMV-infected fibroblasts (HCMV). Results were obtained from the same 
samples as shown in panel a, and this full-length p137 PCR was independently performed twice on the same samples with equivalent results. (c) p137 RNA 
was analyzed by RT-PCR from a new group of rats treated with 6-OHDA or rats treated with RVG9R–p137 or RVG9R–pXef, before 6-OHDA insult (left).  
Duplicate samples are shown with (+) and without () RT. Additionally, RNA from equivalent amounts of mitochondrial (mito) and cytosolic (cyto) fractions  
or total sample (tot), from 6-OHDA rats pretreated with RVG9R–p137, was isolated and analyzed for the presence of p137 RNA by RT-PCR with (+) and without 
() RT (middle). The relative purity of the fractions was also assessed by Western blot analysis (right) using antibodies to HSP60 (mitochondrial marker) and 
GAPDH (cytosolic marker). This PCR and immunoblotting analysis was performed once. As we believed it was necessary to analyze as pure a mitochondrial 
fraction as possible for the presence of p137 RNA, we used an extremely stringent mitochondrial isolation protocol, which resulted in some contamination of 
the cytosolic fraction with mitochondrial proteins. (d) Complex I activity (shown as arbitrary units) was analyzed in nigral tissues from sham-treated rats (n = 4), 
rats treated with 6-OHDA (n = 4), and rats receiving RVG9R–pXef (n = 3) or RVG9R–p137 (n = 5) 3 d before 6-OHDA lesion. Results were derived from one 
analysis, but equivalent trends were observed in two other independent assays. (e) A resazurin reduction assay (shown as relative OD590) was used to assess 
mitochondrial respiration. Mitochondria were isolated from the nigra of sham-treated rats, rats treated with 6-OHDA, and rats treated with RVG9R–p137  
or RVG9R–pXef before 6-OHDA insult (n = 3 per group). Where designated, assays were also performed on the mitochondrial samples in the presence of the 
mitochondrial respiration inhibitors antimycin A and sodium azide, which are specific for inhibiting Complex III and Complex IV, respectively. Data represent 
mean ± SEM; *, P < 0.05 compared with sham; and +, P < 0.05 compared with 6-OHDA.
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Semipurified mitochondria were isolated from the nigra of 
rats treated with RVG9R–p137 or RVG9R–pXef before 
an acute 6-OHDA lesion. Univariate analysis of variance 
showed that there was a significant difference in Complex I 
activity between groups (P = 0.013), and post-hoc analysis 
revealed that there was a significant reduction in Complex I 
activity in rats receiving an acute 6-OHDA insult. A similar 
attenuation on Complex I activity was seen in the lesioned 
rats receiving RVG9R–pXef pretreatment. In contrast, 
mitochondria from rats pretreated with RVG9R–p137 
demonstrated a significant protection of Complex I enzyme 
activity. Such protection in mitochondrial function was also 
confirmed using a resazurin reduction–based assay (Fig. 2 e). 
Respiration in purified mitochondria from rats treated with 
6-OHDA was substantially inhibited compared with mito-
chondria from sham-treated rats, as expected. In contrast, 
rats pretreated with RVG9R–p137 demonstrated a pro-
tected mitochondrial function that was not observed in the 
RVG9R–pXef-pretreated rats.
Collectively, these results suggest that RVG9R–p137 
pretreatment clearly mediates a robust protective effect to 
enhance dopaminergic cell survival against an acute 6-OHDA 
lesion. Such protection is associated with a specific inter-
action between p137 and Complex I, as well as the attenuation 
of 6-OHDA–mediated impairment of Complex I activity 
and mitochondrial respiratory function.
Repeated RVG9R–p37 treatment attenuates 6­OHDA 
toxicity in a progressive lesion model without eliciting  
a host immune response
Although our data showed that we could prevent cell death 
using RVG9R–p137 when delivered before 6-OHDA 
lesion, it is clinically more relevant to show protective effects 
after a lesion had been initiated. Therefore, we investigated 
whether the RVG9R–p137 treatment could mediate a neu-
roprotective function to attenuate cell loss after the onset of 
lesion by using a progressive lesion model of PD. It has been 
well reported that a partial and retrograde nigrostriatal dopa-
minergic degeneration can be achieved by 6-OHDA injec-
tion into the ventrolateral striatum (Kirik et al., 1998; Blandini 
et al., 2007), which causes a progressive cell death over a 
2–6-wk period. Similar to the aforementioned pretreatment 
experiments, a significant correction of behavioral deficits 
(Table 1), as well as a rescue of nigral and striatal tyrosine 
hydroxylase (TH) expression (not depicted), was observed 
with repeated intranigral administrations of RVG9R–p137 
starting 3 d after the intrastriatal 6-OHDA lesion. Such pro-
tection was not observed in rats receiving RVG9R–pXef 
under an equivalent treatment regimen. Clearly, RVG9R–p137 
treatment was able to attenuate 6-OHDA toxicity in a pro-
gressive lesion model when delivered directly to the SNc 
after the initiation of lesion.
We then evaluated whether a comparable neuropro-
tective effect of RVG9R–p137 could be obtained by an 
intravenous route of administration. Rats were given four 
separate injections of 300 µg RVG9R–p137 via the tail 
vein 1–2 d after the lesion, with a further injection 8 d 
after the lesion, and with this last treatment, some animals 
were given FITC-tagged RVG9R–p137 for confocal 
microscopy analysis to evaluate the distribution of p137. 
Consistent with our observations using repeated intrani-
gral delivery, a significant neuroprotection was detected 
only in animals receiving RVG9R–p137 treatment (Fig. 3, 
a–c; and Table 1). Densitometric analysis of striatal TH 
expression revealed significantly higher TH levels in rats 
receiving RVG9R–p137 (85.3 ± 3.9% of the contralateral 
side) compared with those given RVG9R–pXef (51.4 ± 
4.1% of the contralateral side; P < 0.001). This correlated 
with the unbiased stereological counting showing that the 
number of dopaminergic cells in the SNc (6,182 ± 221 per 
contralateral side) was 54.2 ± 8.0% in the RVG9R–pXef, 
compared with 71.2 ± 3.8% in the RVG9R–p137-treated 
group (P < 0.01). Fluorescent detection of FITC, TH, and 
a3/a5 nicotinic AChR in the nigra revealed that many, 
but not all TH-expressing neurons were a3/a5 nicotinic 
AChR positive (Fig. 3 d, arrows) and that detection of p137 
RNA was exclusively restricted to the AChR-expressing 
cells (Fig. 3, d and e). p137 could also be found associ-
ated with cells other than dopaminergic neurons (Fig. 3 e, 
arrows), supporting the possibility that RVG9R-mediated 
p137 delivery could also be used to target cell populations 
other than the dopaminergic system. No FITC signal 
could be found in rats given untagged RVG9R–p137 
treatment (not depicted). There was a tendency for the 
p137 RNA to be recruited toward the site of a more 
severe lesion, i.e., the ipsilateral nigra, after intravenous 
RVG9R–p137 delivery. This preferential recruitment of 
p137 corresponds well with our immunoprecipitation data 
(Fig. 2 a). To determine whether repeated intravenous in-
jections with a large RNA–protein complex stimulates a 
host immune reaction, we compared the level of CD3 and 
ED1 expression between sections from RVG9R–p137 
(ipsilateral/contralateral sides), RVG9R–pXef (ipsilateral 
side), and naive animals. Immunostaining revealed no 
overt changes in the levels of T cell infiltration (CD3; Fig. 4 a) 
and microglial activation (ED1; Fig. 4 b) after repeated 
delivery of RVG9R–p137, other than those elicited by 
the lesioning procedure itself. This is consistent with a 
lack of immune responses observed by Kumar et al. (2007). 
We also ruled out the possibility that RVG9R–p137 treat-
ment generated peptide-specific T cell or antibody re-
sponses. PBMCs from rats treated with RVG9R–p137 by 
repeated tail vein injections and subsequently stimulated 
with RVG9R peptide failed to elicit an IFN- response. 
In contrast, positive controls stimulated with ionomycin 
and PMA generated a strong response, as expected (Fig. 4 c). 
We also analyzed serum from the same animals for 
RVG9R-specific antibodies by ELISA (Fig. 4 d) and found 
that there was no difference in the antibody responses to 
RVG9R peptide between rats injected with RVG9R–
p137 and saline. Overall, it is clear that the RVG9R– 
p137 complex delivered transvascularly does protect TH+  
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putative kinase 1), and parkin genes. Many of these genes are 
thought to have effects on mitochondrial function, reinforc-
ing the view that mitochondrial dysfunction may lie at the 
heart of this disorder, even though the majority of patients 
with PD have an idiopathic disease origin. As such, it would 
have been useful to study the effects of RVG9R–p137 in 
transgenic models of PD, except that none of these models 
show consistent dopaminergic cell loss (Dawson et al., 2010), 
hence our use of neurotoxin-based models. These models, 
although a poor imitation of the clinical condition, have nev-
ertheless been important in the development of a whole range 
of therapeutic agents such as dopaminergic cell transplants 
neurons in a progressive PD model and that this treatment 
is nonimmunogenic.
Since the first demonstration that mitochondrial Com-
plex I activity was impaired in the nigra of patients with PD 
(Schapira et al., 1990), there has been interest in the etiologi-
cal role of mitochondria in PD. Therapeutic agents that 
enhance mitochondrial functions, such as coenzyme Q10, 
have been reported to have a moderate effect in slowing dis-
ease progression in patients with early PD (Shults et al., 2002). 
Of late, several Mendelian genetic causes for PD have been 
identified, including abnormalities in the a-synuclein, LRRK2 
(leucine-rich repeat kinase 2), DJ-1, PINK1 (PTEN-induced 
Figure 3. Intravenous delivery of RVG9R–p37 attenuates the loss of dopaminergic expression in a progressive rat model of PD, and the 
expression of FITC­tagged p37 colocalized with AChR and TH­expressing cells in the nigra. (a–c) Representative pictures of the rostrocaudal 
levels of the striatum and substantia nigra from rats receiving sham (a), RVG9R–pXef (pXef; b), or RVG9R–p137 (p137; c), delivered via the tail vein, after 
the initiation of a progressive intrastriatal 6-OHDA lesion. (d and e) The pattern of p137 detection in the contralateral (p137-contra) and ipsilateral (p137-
ipsi) substantia nigra after intravenous delivery of FITC-tagged RVG9R–p137 was examined by fluorescent confocal microscopy for p137 RNA (red), 
a3/a5 nicotinic AChR (blue), TH (green), and an overlay of the three channels. Arrows in d highlight the fact that not all TH neurons are AChR+, but p137 
expression is restricted to AChR+ cells. Arrows in e highlight the fact that p137 expression can also be found in AChR+, nondopaminergic cells. Immuno-
histochemical analysis was performed once on all animals receiving repeated intravenous RVG9R–p137 (n = 6) and RVG9R–pXef (n = 6) treatments.  
The data shown are from one representative animal. Bars: (a–c, left) 1,000 µm; (a–c, right) 500 µm; (d and e) 40 µm.
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such as neurons, astrocytes, and oligodendrocytes via trans-
vascular administration (Alvarez-Erviti et al., 2011).
Although we did not examine the expression of p137 out-
side the brain after transvascular delivery, Kumar et al. (2007) 
used flow cytometry to analyze the RVG9R-mediated GFP ex-
pression in the peripheral tissues and concluded that the cargo 
delivery was restricted to the CNS. Such a CNS-targeted me-
thod of transvascular delivery suggests that our RVG9R–p137 
complex may be helpful for clinical application in the future 
treatment of PD and related neurodegenerative conditions. 
However, more work is needed to determine the pharmacoki-
netic profile of the RVG9R–p137 conjugate, and work is on-
going to improve the half-life of siRNA in vivo, such as lipid 
encapsulation (Morrissey et al., 2005) and chemical modifica-
tion for polyethylene glycol addition (Dassie et al., 2009).
In conclusion, we have developed a novel therapeutic agent 
that specifically targets Complex I and when given is neuropro-
tective in a range of model systems of dopaminergic cell loss 
mimicking PD, while not inducing any immune reactions. As 
such, this agent has great potential as a disease-modifying therapy 
for this common, incurable neurodegenerative condition.
and, more controversially, glial cell line–derived neurotrophic 
factor (Gill et al., 2003; Lang et al., 2006). The defining path-
ological feature of PD is traditionally considered to be the 
loss of the nigrostriatal pathway, even though the disease is 
now recognized to have a range of nonmotor features and 
extranigral pathology. Indeed, this has even led some to con-
sider PD as a multistage disease with nigral pathology only 
emerging halfway through that disease cascade (Braak et al., 
2006). This, coupled with the heterogeneous nature of PD, 
may limit the potential benefits of current cell replacement 
(Freed et al., 2001; Olanow et al., 2003) and neuroprotective 
(Nutt et al., 2003; Lang et al., 2006) therapies that only target 
neurons of the dopaminergic system. The RVG9R–p137 
treatment reported in this paper may therefore offer a more 
useful alternative by targeting mitochondrial stress in both 
dopaminergic and nondopaminergic cells affected by the dis-
ease process, all of which could be reached through the sys-
temic delivery of the agent assuming that the relevant cell 
populations affected express the right AChR. This has also 
been reinforced by a recent study, showing that the RVG 
peptide can target siRNA delivery to different CNS cells 
Figure . Delivery of RVG9R–p37 via the intravenous route stimulates no apparent immune responses after repeated administration.  
(a) The striatum or substantia nigra of rats repeatedly treated with RVG9R–pXef or RVG9R–p137 via the tail vein after the initiation of intrastriatal  
6-OHDA lesion. Immunostaining using anti-CD3 was performed on naive rats, the contralateral side of rats receiving RVG9R–p137 (p137 contra), the 
ipsilateral side of rats receiving RVG9R–p137 (p137 ipsi), and the ipsilateral side of rats receiving RVG9R–pXef (pXef ipsi). The minor up-regulation of CD3 
signal was caused by the surgical procedure in generating the lesion. (b) Immunostaining for ED1 was performed as in panel a, and again the only appar-
ent up-regulation in ED1 response was caused by the lesioning procedure. Immunohistochemical analysis was carried out once on all animals receiving 
no lesion (n = 3), repeated intravenous treatments of RVG9R–p137 (n = 6), and RVG9R–pXef (n = 6). The data shown are from one representative animal 
of each group. Bars: (a and b, top) 1,000 µm; (a and b, bottom) 500 µm. (c) PBMCs from duplicate rats receiving RVG9R–p137 or saline by repeated tail 
vein injection were stimulated with media alone, RVG9R peptide (peptide), or ionomycin + PMA (positive control). Cells expressing IFN- were then  
assayed by ELISPOT, read on an AID ELISPOT reader, and enumerated using ImageJ. (d) Sera from the same duplicate rats receiving RVG9R–p137 or saline, 
used in c for the IFN- ELISPOT analysis, were also analyzed for RVG9R-specific antibodies using RVG9R-coated ELISA plates. Wells coated with ZNF785 
peptide (anti-ZNF) were used as positive controls for peptide-specific detection. ELISA plates (OD) were read at 450 nm on a Multitek ELISA plate reader.  
(c and d) Assays were performed from three independent experiments. Data represent mean ± SEM; *, P < 0.05; and ***, P < 0.001 compared with immune 
responses stimulated in animals receiving repeated RVG9R–p137 treatments.
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experiments, the conjugates were directly injected into the SNc for intracra-
nial delivery or administered via the tail vein for intravenous delivery 3 d 
before a single 6-OHDA lesion and on every 10th day thereafter. For the 
progressive lesion experiments, the conjugates were delivered intranigrally 
on the third day and then on every 10th day after the intrastriatal 6-OHDA 
lesion. Intravenous conjugate deliveries were given on the first, second, and 
eighth day after lesion.
Behavioral tests. The extent of striatal dopaminergic denervation was 
examined by 2.5 mg/kg amphetamine– and 1.6 mg/kg apomorphine– 
induced rotational behavior. The number of full ipsi- and contralateral 
rotations was measured for 90 min after drug administration. The paw-
reaching test was developed to evaluate the sensorimotor function of the 
animal’s forelimb. In brief, the experimenter firmly held both hindlimbs 
and one forelimb of the animal and moved the rat sideways across a plat-
form over 1 m in 5 s. The unrestrained forelimb was in contact with the 
platform and the number of adjustment steps performed by the rats counted 
in the forehand direction. The animals were habituated to the handling 
associated with this test for three consecutive days before lesion. The cylin-
der test evaluated the spontaneous forelimb use during vertical exploration. 
In brief, the animal was allowed to move freely in a Plexiglas cylinder dur-
ing a 5-min session. The observation was videotaped, with mirrors placed 
behind the cylinder to ensure full visibility of paw placements during this 
time. Data were presented as the proportion of contralateral paw touches 
against the total. Behavioral tests were assessed between the third and 
fourth week after the 6-OHDA lesion. Further details can be found in 
Kuan et al. (2007).
Immunohistochemistry and FISH. Animals were sacrificed by pento-
barbitone sodium and transcardially perfused 4 wk (2 wk for the rats receiv-
ing a transvascular, postlesion treatment) after lesion. The brains were 
removed, postfixed, and then transferred to 30% sucrose until they sank. 
40-µm coronal brain sections were cut, and a 1:6 series of sections were 
immunostained for mouse anti-TH (1:500; Millipore), anti-AChR a3/a5 
(1:1,000; Sigma-Aldrich), anti-ED1 (1:1,000; AbD Serotec), and anti-CD3 
(1:500; Abcam) as described previously (Kuan et al., 2006, 2007). The cul-
tures or sections were visualized either by immunofluorescence (Alexa Fluor 
568 and Alexa Fluor 688; 1:1,000; both from Invitrogen) or diaminobenzi-
dine. Staining omitting primary antibodies was performed in all immuno-
histochemical experiments to serve as a negative control.
For FISH to detect p137 RNA, cells were washed, fixed with 4% para-
formaldehyde, and permeabilized with 70% cold ethanol. Cells were then 
rehydrated in 2× SSC (saline sodium citrate), and incubated with blocking 
buffer (50% formamide, 2× SSC, 10% dextran sulfate, 1× Denhardt’s solu-
tion, 2 mM ribonucleoside vanadyl complexes, 50 µg/ml of yeast tRNA, 
and 50 µg/ml of salmon sperm DNA) for 30 min at 37°C in a humidified 
incubator followed by overnight hybridization with 0.4 ng/ml Cy3-labeled 
antisense probe for p137 in the same buffer. After hybridization, cells were 
counterstained with 1 mg/ml Hoechst and mounted with Citifluor (Dako) 
and analyzed by fluorescence microscopy (Eclipse TE300; Nikon).
Determination of Complex I activity. To compare changes in mitochon-
drial Complex I activity, mitochondria were isolated from the SNc. To do 
this, rats were decapitated under general anesthesia. Upon removal of the 
brain, a 70–90-mg nigral tissue was acutely dissected and immediately sub-
merged in ice-cold artificial cerebrospinal flood (125 mM NaCl, 5 mM KCl, 
1.25 mM NaH2PO4, 28 mM NaHCO3, 0.5 mM CaCl2, 4 mM MgCl2, 
25 mM d-glucose, and 1 mM kynurenic acid). Mitochondrial preparations were 
obtained from brain sections using a proprietary mitochondria isolation 
kit (BioChain Institute) as described by the manufacturer. For analysis of 
Complex I activity in these mitochondria, a Complex I Enzyme Activity 
Microplate Assay kit (MitoSciences) was used exactly as described by the 
manufacturer. In all cases, samples were corrected for total mitochondrial 
protein assayed.
Mitochondrial respiration was also analyzed directly using a resazurin 
reduction assay of isolated mitochondria in a 96-well plate format, as 
MATERIALS AND METHODS
Peptides. Peptide RVG9R (YTIWMPENPRPGTPCDIFTNSRGKRAS-
NGGGGRRRRRRRRRR) comprises a short peptide derived from the 
RVG and nine C-terminal arginine residues that were d-arginine (Kumar 
et al., 2007). We also used a control peptide, RVMat9R, in which the RVG 
sequences were replaced with amino acids from the rabies virus matrix pro-
tein, which does not bind to the AChR (Kumar et al., 2007). At least five 
separate batches of peptide for use in the experiments described in this paper 
were synthesized by Pro-Immune Ltd. and supplied as a lyophilized powder. 
For use experimentally, it was suspended in water at a concentration of 
20 mg/ml and stored at 70°C.
RNAs. All RNAs were transcribed from linear DNA templates in vitro 
using a MEGAscript polymerase kit (Invitrogen; as described by the manu-
facturer). 2.7 RNA (containing nucleotides 4,577–3,782 of the 2.7 gene 
in HCMV strain AD169) was transcribed with T7 from p137 plasmid 
(Bergamini et al., 1998) after linearization with XhoI. Alternatively, control 
antisense p137 RNA was generated by linearization with HindIII and tran-
scription using SP6. Additional control RNA was derived from the pTri-Xef 
(Invitrogen), a prelinearized plasmid template encoding the Xenopus laevis 
elongation factor 1a gene. FITC-labeled p137 RNA was produced using 
a fluorescein RNA labeling mix (Roche) in conjunction with the 
MEGAscript kit, substituting the kit’s supplied NTP mixtures with the fluo-
rescein NTP mix (as described by the manufacturer). Multiple batches of 
control and specific RNAs were used over the course of these experiments. 
To generate the p137-specific probe (antisense) for fluorescence in situ hy-
bridization (FISH), the p137 plasmid was linearized with HindIII and used as a 
template for in vitro transcription as described above except that Cy3-UTP 
(GE Healthcare) was used as described by the manufacturer to incorporate 
Cy3 label into the in vitro transcribed p137 RNA.
RNA–peptide complex. RNAs, RVG9R, and RVMat9R were com-
bined in a 10:11 (peptide/RNA) molar ratio, with serum-free MEM making 
up the total volume. For visualization of peptide–RNA complex on cells, a 
spike of FITC-labeled RNA (1:20 labeled/unlabeled for in vitro experi-
ments and 1:4 labeled/unlabeled for in vivo imaging) was included during 
peptide–RNA complex formation.
Cell cultures. U373 glioblastoma cells were grown in Earle’s MEM contain-
ing 10% fetal calf serum. SH-SY5Y neuroblastoma and HEK293 embryonic 
kidney cells were grown in DMEM. All media contained penicillin/strep-
tomycin, and all cells were grown at 37°C in 5% CO2. Primary cell cultures 
were made of embryonic day (E) 13.5 rat ventral mesencephalic (VM) tissue. 
Fetal VM tissues were dissected using standard procedures and mechanically 
dissociated to a single cell suspension. Half of the fetal VM was plated per 
poly-l-lysine–coated glass coverslip in differentiation medium containing 
RVG9R–p137 or RVG9R–pXef at various concentrations. Further details 
on the culture preparation can be found in Kuan et al. (2006). The primary 
cells were then challenged by 6-OHDA for 24 h and fixed after 7 d in vitro 
growth for immunocytochemical analysis.
TUNEL assay. TUNEL staining to detect apoptosis was performed using 
an In situ Cell Death Detection kit, TMR red (Roche) exactly as described 
by the manufacturer.
Surgical procedures. Male Sprague-Dawley rats, weighing around 200 g 
at the time of initial surgery, were housed with unrestricted access to food 
and water. All animal experiments were performed in compliance with the 
UK Animals (Scientific Procedures) Act 1986. Each animal was given noro-
carp and terramycin before surgery, followed by injection of 18 µg/3 µl 
6-OHDA to the SNc for an acute lesion (anterior–posterior, 5.3 mm; 
medial–lateral, 2.0 mm; dorsal–ventral, 7.2 mm) or 24 µg/4 µl to the 
striatum for a progressive lesion (anterior–posterior, 1.0 mm; medial–lateral, 
3.0 mm; dorsal–ventral, 5.0 mm). All coordinates were based on Paxinos 
and Watson (1986) and are relative to bregma and the dural surface with 
the incisor bar set 2.3 mm below the interaural line. For the pretreatment 
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Microscopy, densitometric, stereological, and statistical analysis. 
Imaging was performed using a DM6000 microscope or a TCS SP2 confocal 
microscope (Leica). The mean OD was determined by subtracting the OD 
of the background from the region of interest defined by TH staining. 
Results were expressed as the ratio between the OD of the ipsi- and contra-
lateral side. Total cell numbers in the SNc were estimated by unbiased stere-
ology sampling using the Stereo Investigator 9.10.3 (MBF Bioscience). 
Densitometric, stereological, and behavioral data between all groups of ani-
mals was analyzed using univariate analysis of variance, and a post-hoc Bon-
ferroni test was used as appropriate with significance set at P < 0.05. All the 
analysis was performed using ImageJ 1.42q and SPSS Release 16.0.0.
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previously described (Zhang et al., 2004). After isolation, as described in the 
previous paragraph, mitochondria were analyzed directly or after pre-
treatment with 25 µg/ml antimycin A or 650 µM sodium azide, which are 
specific inhibitors of mitochondrial respiration and confirmed that the 
mitochondrial-specific component of respiration analyses was being assayed.
RNA/protein immunoprecipitation. Nigral tissue was prepared exactly 
as detailed in the previous section for preparation of mitochondria and enzy-
matically digested with trypsin (Worthington). The digestion was terminated 
with a mixture of trypsin inhibitor and DNase (both from Sigma-Aldrich). 
After centrifugation, the pellet was resuspended in DMEM and mechanically 
triturated until a single cell suspension had formed. The cells were then fixed 
in paraformaldehyde, quenched in glycine, and stored at 80°C until used. 
To determine any interaction of p137 RNA with Complex I, cells derived 
from the SNc of rats treated intranigrally with RVG9R–p137 or RVG9R–
pXef were subject to RNA immunoprecipitation using Complex I and 
Complex IV immunocapture beads (MitoSciences) as described by the man-
ufacturer. The anti–Complex I antibody used only recognizes fully formed 
native Complex I assembled in the mitochondria. Ig2a antibody–coated 
beads were also used as an additional control for the immunoprecipitation. 
After immunocapture of Complex I or Complex IV from the samples, the 
presence of interacting p137 RNA was analyzed by RT-PCR, as previously 
described (Reeves et al., 2007).
To assess the relative levels of localization of p137 RNA in mitochon-
dria and the cytosol, mitochondria were isolated using the proprietary mito-
chondria isolation kit (BioChain Institute), and RNA isolated from each 
cellular subfraction by TRIZOL extraction was analyzed by p137-specific 
RT-PCR (Reeves et al., 2007). Relative purity of the fractions was assessed 
using Western blot analysis with antibodies to HSP60 (specific for mito-
chondria) and GAPDH (specific for cytosol).
Assessment of peptide-specific T cell and antibody responses in 
treated rats. Blood was collected from rats by heart puncture (8 ml blood 
in 2 ml of 100 U/ml heparin sodium), and PBMCs were isolated by density 
barrier centrifugation using a 2.5:2 vol/vol ratio of OptiPrep (Axis-Shield) 
and tricine buffer (10 mM tricine and 0.145 M NaCl, pH 7.0). Heparinized 
rat blood was diluted 1:1 with tricine buffer and 6 ml of diluted blood lay-
ered onto 3 ml of a density barrier and centrifuged at 800 g for 20 min. The 
PBMCs were removed from the interface with a Pasteur pipette and diluted 
in PBS (Oxoid) and washed twice before resuspension and counting in 
RPMI 1640 10% FCS.
Rat IFN- ELISPOT assays were performed according to the manufac-
turers protocols (BD). In brief, PBMCs from two RVG- and two saline-
inoculated animals were used at 1.875 3 105 and 3.75 3 105 cells per well 
in triplicate. Wells were stimulated with media alone (as a negative control), 
media containing 20 µg/ml RVG peptide, or media containing 500 ng/ml 
ionomycin and 5 ng/ml PMA (positive control). ELISPOT plates were in-
cubated overnight at 37°C in 5% CO2 and then developed according to the 
manufacturers protocols. Plates were read on a Reader System, AID ELISPOT 
reader and enumerated using ImageJ (National Institutes of Health).
For antibody analysis, 96-well ELISA (Thermo Fisher Scientific) plates 
were coated with 0.1 µg per well of either RVG9R peptide or ZNF785 
peptide (Abcam; as a positive control for peptide-specific ELISA detection) 
in bicarbonate buffer overnight at 4°C. Plates were washed three times in 
PBS 0.05% Tween-20 (PBST), and 200 µl of 10 mg/ml bovine serum albu-
min in PBST was added to each well for 2 h at 37°C as a blocking agent. Rat 
sera from saline- or RVG peptide–treated rats or rat sera specific for ZNF785 
peptide was diluted 1:1,600 in PBST 3% BSA (antibody dilution buffer), and 
100 µl was added to peptide-coated wells and incubated for 1 h at 37°C. 
Plates were washed five times in PBST. Anti–rat horseradish peroxidase was 
diluted 1:4,000 in antibody dilution buffer, and 100 µl was added to each 
well, incubated for 30 min at 37°C, and then washed five times. 50 µl TMB 
substrate (eBioscience) was added per well, and 50 µl of 2N sulfuric acid was 
added to stop color development. ELISA plates were read at 450 nm on a 
Multitek ELISA plate reader.
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